Action 27. Mobilize their networks and work with communities to help build treatment literacy, generate demand, and expand access to ARVs among children.
Action 34. Increase efforts to share information on the roll-out of new paediatric formulations, including lessons learned.
Paediatric HIV & TB : Rome Action Plan
Continue to convene and coordinate stakeholders at a high level, including the pharmaceutical industry, FBO and civil society service providers, national governments and multilateral partners, and partners in the Start Free, Stay Free, AIDS Free Framework.
UNAIDS and PEPFAR as co-chairs of Start Free, Stay Free AIDS Free Framework
Sub-Actions & Milestones
Continue to convene and coordinate stakeholders at a high level
PEPFAR has been in touch with ViiV and Merck & Co., Inc., about their commitments to make pediatric drugs available to LMIC. The companies confirmed their intention to provide them at access pricing until generics were available, and potentially beyond.
On February 9, 2018, PEPFAR convened over fifty technical experts in Washington, D.C. to address challenges in pediatric HIV case finding, and specifically identification of pre-adolescent children with HIV before they present to facilities with illness. Specifically, the meeting focused on finding younger asymptomatic children living with HIV (<10-12 years old) outside the usual facility-based testing (PITC) and routine PMTCT programs with special interest in using OVC, faith-based, school, and other community platforms. This remains a significant issue for all implementing partners. By the end of the meeting the group developed recommendations for: Effective strategies that can be widely adopted, perhaps with adaptation to context; Strategies that show promise in pilot or small-scale, which should be further evaluated and/or scaled up; and Creative, novel ideas that can be piloted and tested.
On March 29, 2018, PEPFAR convened diagnostics companies, donors, and select implementing partners for a one-day Consultation meeting in New York City on shared issues related to pediatric treatment such as strategies to improve access to HIV (and TB) diagnostics for infants and children in lower middle income countries (LMICs). This meeting served as a follow-on meeting to the November 2017 High-Level Dialogue on Scaling-Up Early Diagnosis and Treatment of Children and Adolescents. The meeting ended up with concrete action items for diagnostic manufacturers to address to ensure cost efficient and uninterrupted diagnosis services for Children and Adolescents.
George Siberry led and moderated the discussion. Ambassador Birx provided opening remarks. Others in attendance were representatives from CMMB, Elizabeth Glaser Pediatric AIDS Foundation, ELMA, FHI360, ICAP, Jhpiego, John Snow, Inc., Mothers2Mothers, Management Sciences for Health, Save the Children, UNICEF, University Research Co., LLC (URC) & Center for Human Services (CHS), ViiV Positive Action, WCC-EAA, World Education Inc., World Health Organziation, and World Vision International.
Ambassador Birx provided opening remarks and participated in side meeting discussions with key attendees. The meeting was attended by individuals from Abbott/Alere, Becton Dickinson, CDC – International Laboratory Branch, Cepheid, Clinton Health Access Initiative, DRW, EGPAF, ELMA, Hologic, Holy See, Orasure, Roche, Columbia University, UNAIDS, UNICEF, UNITAID, WCC-EAA, World Health Organization, and the U.S. Food and Drug Administration.